Peter Klivenyi, MD PhD - Publications

Affiliations: 
Neurology University of Pécs, Hungary, Pécs, Hungary 

72 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Balicza P, Grosz Z, Gonzalez MA, Bencsik R, Pentelenyi K, Gal A, Varga E, Klivenyi P, Koller J, Züchner S, Molnar JM. Genetic background of the hereditary spastic paraplegia phenotypes in Hungary - An analysis of 58 probands. Journal of the Neurological Sciences. 364: 116-21. PMID 27084228 DOI: 10.1016/J.Jns.2016.03.018  0.92
2016 Szpisjak L, Obal I, Engelhardt JI, Vecsei L, Klivenyi P. A novel SETX gene mutation producing ataxia with oculomotor apraxia type 2. Acta Neurologica Belgica. PMID 26811093 DOI: 10.1007/S13760-015-0569-Y  0.92
2016 Kovács N, Horváth K, Aschermann Z, Ács P, Bosnyák E, Deli G, Pál E, Janszky J, Faludi B, Karádi K, Késmárki I, Bokor M, Rigó E, Lajtos J, Klivényi P, et al. Independent validation of Parkinson'S disease Sleep Scale 2nd version (PDSS-2) Sleep and Biological Rhythms. 14: 63-73. DOI: 10.1007/S41105-015-0024-8  0.92
2015 Szalárdy L, Zádori D, Klivényi P, Toldi J, Vécsei L. Electron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial Bioenergetics. Oxidative Medicine and Cellular Longevity. 2015: 498401. PMID 26301042 DOI: 10.1155/2015/498401  0.92
2015 Zádor F, Lénárt N, Csibrány B, Sántha M, Molnár M, Tuka B, Samavati R, Klivényi P, Vécsei L, Marton A, Vizler C, Nagy GM, Borsodi A, Benyhe S, Páldy E. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner. Neuropharmacology. 89: 298-307. PMID 25446673 DOI: 10.1016/J.Neuropharm.2014.10.008  0.92
2015 Török N, Török R, Klivényi P, Engelhardt J, Vécsei L. Investigation of vitamin D receptor polymorphisms in amyotrophic lateral sclerosis Acta Neurologica Scandinavica. DOI: 10.1111/ane.12463  0.92
2015 Zádori D, Máté A, Róna-Vörös K, Gergev G, Zimmermann A, Nagy N, Széll M, Vécsei L, Sztriha L, Klivényi P. The clinical manifestations of two novel SPAST mutations Clinical Neurology and Neurosurgery. 136: 82-85. DOI: 10.1016/j.clineuro.2015.05.009  0.92
2014 Horváth K, Aschermann Z, Acs P, Bosnyák E, Deli G, Pál E, Janszky J, Faludi B, Késmárki I, Komoly S, Bokor M, Rigó E, Lajtos J, Klivényi P, Dibó G, et al. Is the MDS-UPDRS a Good Screening Tool for Detecting Sleep Problems and Daytime Sleepiness in Parkinson's Disease? Parkinson's Disease. 2014: 806169. PMID 25506041 DOI: 10.1155/2014/806169  0.92
2014 Tánczos T, Zádori D, Jakab K, Hnyilicza Z, Klivényi P, Keresztes L, Engelhardt J, Németh D, Vécsei L. The role of cognitive training in the neurorehabilitation of a patient who survived a lightning strike. A case study. Neurorehabilitation. 35: 137-46. PMID 24990020 DOI: 10.3233/Nre-141106  0.92
2014 Zádori D, Veres G, Szalárdy L, Klivényi P, Toldi J, Vécsei L. Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets. Journal of Alzheimer's Disease : Jad. 42: S177-87. PMID 24670398 DOI: 10.3233/Jad-132621  0.92
2013 Szalardy L, Zadori D, Tanczos E, Simu M, Bencsik K, Vecsei L, Klivenyi P. Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis. Neuroscience Letters. 554: 131-4. PMID 24021801 DOI: 10.1016/J.Neulet.2013.08.069  0.92
2013 Török R, Török N, Szalardy L, Plangar I, Szolnoki Z, Somogyvari F, Vecsei L, Klivenyi P. Association of vitamin D receptor gene polymorphisms and Parkinson's disease in Hungarians. Neuroscience Letters. 551: 70-4. PMID 23880018 DOI: 10.1016/J.Neulet.2013.07.014  0.92
2013 Szalardy L, Zadori D, Simu M, Bencsik K, Vecsei L, Klivenyi P. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity. Journal of the Neurological Sciences. 331: 38-42. PMID 23706476 DOI: 10.1016/J.Jns.2013.04.024  0.92
2013 Szalardy L, Zadori D, Plangar I, Vecsei L, Weydt P, Ludolph AC, Klivenyi P, Kovacs GG. Neuropathology of partial PGC-1α deficiency recapitulates features of mitochondrial encephalopathies but not of neurodegenerative diseases. Neuro-Degenerative Diseases. 12: 177-88. PMID 23406886 DOI: 10.1159/000346267  0.92
2013 Zádori D, Szalárdy L, Toldi J, Fülöp F, Klivényi P, Vécsei L. Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 120: 673-81. PMID 23196983 DOI: 10.1007/S00702-012-0930-8  0.92
2012 Szalardy L, Zadori D, Toldi J, Fulop F, Klivenyi P, Vecsei L. Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction. Current Topics in Medicinal Chemistry. 12: 1797-806. PMID 23030614 DOI: 10.2174/156802612803989264  0.92
2012 Klivényi P, Nemeth D, Sefcsik T, Janacsek K, Hoffmann I, Haden GP, Londe Z, Vecsei L. Cognitive functions in ataxia with oculomotor apraxia type 2. Frontiers in Neurology. 3: 125. PMID 23015802 DOI: 10.3389/Fneur.2012.00125  0.92
2012 Zádori D, Klivényi P, Szalárdy L, Fülöp F, Toldi J, Vécsei L. Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: novel therapeutic strategies for neurodegenerative disorders. Journal of the Neurological Sciences. 322: 187-91. PMID 22749004 DOI: 10.1016/J.Jns.2012.06.004  0.92
2012 Nemeth D, Dye CD, Sefcsik T, Janacsek K, Turi Z, Londe Z, Klivenyi P, Kincses ZT, Szabó N, Vecsei L, Ullman MT. Language deficits in pre-symptomatic Huntington's disease: evidence from Hungarian. Brain and Language. 121: 248-53. PMID 22538085 DOI: 10.1016/J.Bandl.2012.04.001  0.92
2012 Szalardy L, Klivenyi P, Zadori D, Fulop F, Toldi J, Vecsei L. Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects. Current Medicinal Chemistry. 19: 1899-920. PMID 22429096 DOI: 10.2174/092986712800167365  0.92
2012 Kincses ZT, Szabó N, Valálik I, Kopniczky Z, Dézsi L, Klivényi P, Jenkinson M, Király A, Babos M, Vörös E, Barzó P, Vécsei L. Target identification for stereotactic thalamotomy using diffusion tractography. Plos One. 7: e29969. PMID 22238685 DOI: 10.1371/Journal.Pone.0029969  0.92
2012 Zádori D, Klivényi P, Toldi J, Fülöp F, Vécsei L. Kynurenines in Parkinson's disease: therapeutic perspectives. Journal of Neural Transmission (Vienna, Austria : 1996). 119: 275-83. PMID 21858430 DOI: 10.1007/S00702-011-0697-3  0.92
2011 Nagy K, Plangár I, Tuka B, Gellért L, Varga D, Demeter I, Farkas T, Kis Z, Marosi M, Zádori D, Klivényi P, Fülöp F, Szatmári I, Vécsei L, Toldi J. Synthesis and biological effects of some kynurenic acid analogs. Bioorganic & Medicinal Chemistry. 19: 7590-6. PMID 22079867 DOI: 10.1016/J.Bmc.2011.10.029  0.92
2011 Klivenyi P, Vecsei L. Pharmacological models of Parkinson's disease in rodents. Methods in Molecular Biology (Clifton, N.J.). 793: 211-27. PMID 21913103 DOI: 10.1007/978-1-61779-328-8_14  0.92
2011 Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, ... ... Klivenyi P, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: 386-395.e6. PMID 21784349 DOI: 10.1016/J.Jalz.2011.05.2243  0.92
2011 Plangár I, Zádori D, Klivényi P, Toldi J, Vécsei L. Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy. Journal of Alzheimer's Disease : Jad. 24: 199-209. PMID 21441658 DOI: 10.3233/Jad-2011-110131  0.92
2011 Zádori D, Ilisz I, Klivényi P, Szatmári I, Fülöp F, Toldi J, Vécsei L, Péter A. Time-course of kynurenic acid concentration in mouse serum following the administration of a novel kynurenic acid analog. Journal of Pharmaceutical and Biomedical Analysis. 55: 540-3. PMID 21392919 DOI: 10.1016/J.Jpba.2011.02.014  0.92
2011 Zádori D, Nyiri G, Szonyi A, Szatmári I, Fülöp F, Toldi J, Freund TF, Vécsei L, Klivényi P. Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 118: 865-75. PMID 21194001 DOI: 10.1007/S00702-010-0573-6  0.92
2011 Zádori D, Klivényi P, Plangár I, Toldi J, Vécsei L. Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. Journal of Cellular and Molecular Medicine. 15: 701-17. PMID 21155972 DOI: 10.1111/J.1582-4934.2010.01237.X  0.92
2010 Spitzer P, Klafki HW, Blennow K, Buée L, Esselmann H, Herruka SK, Jimenez C, Klivenyi P, Lewczuk P, Maler JM, Markus K, Meyer HE, Morris C, Müller T, Otto M, et al. cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. International Journal of Alzheimer's Disease. 2010. PMID 20886057 DOI: 10.4061/2010/548145  0.92
2010 Vamos E, Voros K, Vecsei L, Klivenyi P. Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease. Biomedicine & Pharmacotherapy = BioméDecine & PharmacothéRapie. 64: 282-6. PMID 19932584 DOI: 10.1016/J.Biopha.2009.06.020  0.92
2010 Klivenyi P, Vecsei L. Novel therapeutic strategies in Parkinson's disease. European Journal of Clinical Pharmacology. 66: 119-25. PMID 19834698 DOI: 10.1007/S00228-009-0742-4  0.92
2009 Zádori D, Klivényi P, Vámos E, Fülöp F, Toldi J, Vécsei L. Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. Journal of Neural Transmission (Vienna, Austria : 1996). 116: 1403-9. PMID 19618107 DOI: 10.1007/S00702-009-0263-4  0.92
2009 Vamos E, Voros K, Zadori D, Vecsei L, Klivenyi P. Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 116: 1079-86. PMID 19551467 DOI: 10.1007/S00702-009-0253-6  0.92
2009 Vamos E, Pardutz A, Klivenyi P, Toldi J, Vecsei L. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. Journal of the Neurological Sciences. 283: 21-7. PMID 19268309 DOI: 10.1016/J.Jns.2009.02.326  0.92
2009 Kovacs N, Auer T, Balas I, Karadi K, Zambo K, Schwarcz A, Klivenyi P, Jokeit H, Horvath K, Nagy F, Janszky J. Neuroimaging and cognitive changes during déjà vu. Epilepsy & Behavior : E&B. 14: 190-6. PMID 18804184 DOI: 10.1016/J.Yebeh.2008.08.017  0.92
2009 Vamos E, Csati A, Vecsei L, Klivenyi P. Effects of valproate on the dopaminergic system in mice. Neurological Research. 31: 217-9. PMID 18768113 DOI: 10.1179/174313208X346099  0.92
2008 Oláh J, Klivényi P, Gardián G, Vécsei L, Orosz F, Kovacs GG, Westerhoff HV, Ovádi J. Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice. The Febs Journal. 275: 4740-55. PMID 18721135 DOI: 10.1111/J.1742-4658.2008.06612.X  0.92
2007 Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Peripheral kynurenine metabolism in focal dystonia. Medicinal Chemistry (ShāRiqah (United Arab Emirates)). 3: 285-8. PMID 17504201 DOI: 10.2174/157340607780620707  0.92
2006 Klivenyi P, Bende Z, Hartai Z, Penke Z, Nemeth H, Toldi J, Vecsei L. Behaviour changes in a transgenic model of Huntington's disease. Behavioural Brain Research. 169: 137-41. PMID 16443291 DOI: 10.1016/J.Bbr.2006.01.003  0.92
2006 Klivenyi P, Siwek D, Gardian G, Yang L, Starkov A, Cleren C, Ferrante RJ, Kowall NW, Abeliovich A, Beal MF. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiology of Disease. 21: 541-8. PMID 16298531 DOI: 10.1016/J.Nbd.2005.08.018  0.92
2005 Klivenyi P, Kekesi KA, Hartai Z, Juhasz G, Vecsei L. Effects of mitochondrial toxins on the brain amino acid concentrations. Neurochemical Research. 30: 1421-7. PMID 16341939 DOI: 10.1007/S11064-005-8512-X  0.92
2005 Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease. Journal of the Neurological Sciences. 239: 31-5. PMID 16099471 DOI: 10.1016/J.Jns.2005.07.006  0.92
2005 Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine metabolism in multiple sclerosis. Acta Neurologica Scandinavica. 112: 93-6. PMID 16008534 DOI: 10.1111/J.1600-0404.2005.00442.X  0.92
2005 Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal MF. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. The Journal of Biological Chemistry. 280: 556-63. PMID 15494404 DOI: 10.1074/Jbc.M410210200  0.92
2004 Klivenyi P, Gardian G, Calingasan NY, Yang L, von Borstel R, Saydoff J, Browne SE, Beal MF. Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity. Neuromolecular Medicine. 6: 87-92. PMID 15970626 DOI: 10.1385/Nmm:6:2-3:087  0.92
2004 Gardian G, Yang L, Cleren C, Calingasan NY, Klivenyi P, Beal MF. Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Medicine. 5: 235-41. PMID 15626823 DOI: 10.1385/Nmm:5:3:235  0.92
2004 Klivenyi P, Calingasan NY, Starkov A, Stavrovskaya IG, Kristal BS, Yang L, Wieringa B, Beal MF. Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiology of Disease. 15: 610-7. PMID 15056469 DOI: 10.1016/J.Nbd.2003.12.014  0.92
2004 Klivenyi P, Starkov AA, Calingasan NY, Gardian G, Browne SE, Yang L, Bubber P, Gibson GE, Patel MS, Beal MF. Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity. Journal of Neurochemistry. 88: 1352-60. PMID 15009635 DOI: 10.1046/J.1471-4159.2003.02263.X  0.92
2004 Klivényi P, Toldi J, Vécsei L. Kynurenines in neurodegenerative disorders: therapeutic consideration. Advances in Experimental Medicine and Biology. 541: 169-83. PMID 14977214 DOI: 10.1007/978-1-4419-8969-7_10  0.92
2004 Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry. 88: 576-82. PMID 14720207 DOI: 10.1046/J.1471-4159.2003.02160.X  0.92
2003 Klivenyi P, Gardian G, Calingasan NY, Yang L, Beal MF. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Journal of Molecular Neuroscience : Mn. 21: 191-8. PMID 14645986 DOI: 10.1385/Jmn:21:3:191  0.92
2003 Karg E, Klivenyi P, Bencsik K, Turi S, Vecsei L. Alpha-tocopherol and NADPH in the erythrocytes and plasma of multiple sclerosis patients. Effect of interferon-beta-1b treatment. European Neurology. 50: 215-9. PMID 14634265 DOI: 10.1159/000073862  0.92
2003 Barberi T, Klivenyi P, Calingasan NY, Lee H, Kawamata H, Loonam K, Perrier AL, Bruses J, Rubio ME, Topf N, Tabar V, Harrison NL, Beal MF, Moore MA, Studer L. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nature Biotechnology. 21: 1200-7. PMID 14502203 DOI: 10.1038/Nbt870  0.92
2003 Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry. 86: 267-72. PMID 12807446 DOI: 10.1046/J.1471-4159.2003.T01-1-01868.X  0.92
2001 Andreassen OA, Ferrante RJ, Klivenyi P, Klein AM, Dedeoglu A, Albers DS, Kowall NW, Beal MF. Transgenic ALS mice show increased vulnerability to the mitochondrial toxins MPTP and 3-nitropropionic acid. Experimental Neurology. 168: 356-63. PMID 11259123 DOI: 10.1006/Exnr.2001.7627  0.92
2001 Klivenyi P, Karg E, Rozsa C, Horvath R, Komoly S, Nemeth I, Turi S, Vecsei L. alpha-Tocopherol/lipid ratio in blood is decreased in patients with Leber's hereditary optic neuropathy and asymptomatic carriers of the 11778 mtDNA mutation. Journal of Neurology, Neurosurgery, and Psychiatry. 70: 359-62. PMID 11181859 DOI: 10.1136/Jnnp.70.3.359  0.92
2001 Andreassen OA, Ferrante RJ, Dedeoglu A, Albers DW, Klivenyi P, Carlson EJ, Epstein CJ, Beal MF. Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. Experimental Neurology. 167: 189-95. PMID 11161607 DOI: 10.1006/Exnr.2000.7525  0.92
2000 Andreassen OA, Dedeoglu A, Klivenyi P, Beal MF, Bush AI. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport. 11: 2491-3. PMID 10943709 DOI: 10.1097/00001756-200008030-00029  0.92
2000 Andreassen OA, Ferrante RJ, Hughes DB, Klivenyi P, Dedeoglu A, Ona VO, Friedlander RM, Beal MF. Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominant-negative mutant. Journal of Neurochemistry. 75: 847-52. PMID 10899963 DOI: 10.1046/J.1471-4159.2000.0750847.X  0.92
2000 Klivenyi P, Andreassen OA, Ferrante RJ, Lancelot E, Reif D, Beal MF. Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity. Neuroreport. 11: 1265-8. PMID 10817604 DOI: 10.1097/00001756-200004270-00024  0.92
2000 Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR, Beal MF. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. Journal of Neurochemistry. 74: 2108-19. PMID 10800956 DOI: 10.1046/J.1471-4159.2000.0742108.X  0.92
2000 Andreassen OA, Ferrante RJ, Klivenyi P, Klein AM, Shinobu LA, Epstein CJ, Beal MF. Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis. Annals of Neurology. 47: 447-55. PMID 10762155 DOI: 10.1002/1531-8249(200004)47:4<447::Aid-Ana7>3.0.Co;2-R  0.92
2000 Klivenyi P, Andreassen OA, Ferrante RJ, Dedeoglu A, Mueller G, Lancelot E, Bogdanov M, Andersen JK, Jiang D, Beal MF. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 1-7. PMID 10627575 DOI: 10.1523/Jneurosci.20-01-00001.2000  0.92
1999 Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Experimental Neurology. 157: 142-9. PMID 10222117 DOI: 10.1006/Exnr.1999.7049  0.92
1999 Matthews RT, Klivenyi P, Mueller G, Yang L, Wermer M, Thomas CE, Beal MF. Novel free radical spin traps protect against malonate and MPTP neurotoxicity. Experimental Neurology. 157: 120-6. PMID 10222114 DOI: 10.1006/Exnr.1999.7045  0.92
1999 Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine. 5: 347-50. PMID 10086395 DOI: 10.1038/6568  0.92
1998 Klivenyi P, St Clair D, Wermer M, Yen HC, Oberley T, Yang L, Flint Beal M. Manganese superoxide dismutase overexpression attenuates MPTP toxicity. Neurobiology of Disease. 5: 253-8. PMID 9848095 DOI: 10.1006/Nbdi.1998.0191  0.92
1998 Bogdanov MB, Ferrante RJ, Kuemmerle S, Klivenyi P, Beal MF. Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. Journal of Neurochemistry. 71: 2642-4. PMID 9832167 DOI: 10.1046/J.1471-4159.1998.71062642.X  0.92
1998 Klivenyi P, Beal MF, Ferrante RJ, Andreassen OA, Wermer M, Chin MR, Bonventre JV. Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. Journal of Neurochemistry. 71: 2634-7. PMID 9832165 DOI: 10.1046/J.1471-4159.1998.71062634.X  0.92
1998 Klivenyi P, Matthews RT, Wermer M, Yang L, MacGarvey U, Becker DA, Natero R, Beal MF. Azulenyl nitrone spin traps protect against MPTP neurotoxicity. Experimental Neurology. 152: 163-6. PMID 9682023 DOI: 10.1006/Exnr.1998.6824  0.92
1998 Bencsik K, Rajda C, Klivenyi P, Jardanhazy T, Torok M, Vecsei L. Therapy of relapsing-remitting multiple sclerosis | A relapszus-remisszio korformaju sclerosis multiplex kezelese Lege Artis Medicinae. 8: 756-760.  0.92
Show low-probability matches.